KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).

Paul Lesueur, Benedicte Clarisse, Justine Lequesne, Idlir Licaj, Loic Feuvret, Dinu Stefan, Damien Ricard, Georges Noel, Jacques Balosso, Marie Lange, Aurelie Capel, Isabelle Durand-Zaleski, Marie Castera, Berenice Legrand, Nicolas Goliot, Camille Hedou, Jean Michel Grellard, Samuel Valable

BMC Cancer 24(1) 1594

PMID39736544
PMCIDPMC11687058
DOI10.1186/s12885-024-13353-9
发表日期2024-12-30
摘要

摘要

BACKGROUND: Proton therapy (PRT) is an innovative radiotherapeutic modality for the treatment of cancer with unique ballistic properties. The depth-dose distribution of a proton beam reduces exposure of healthy tissues to radiations, compared with photon-therapy (XRT). To date, only few indications for proton-therapy, like pediatric cancers, chordomas, or intra-ocular neoplasms, are reimbursed by Health systems. There is no published or recruiting prospective study evaluating the impact of proton-therapy or conventional irradiation on neurocognitive function for meningioma patients. Notably, long-term cognitive or ocular impact of these modern irradiation schemes remains poorly known. Yet, these patients had a long life-expectancy, and are at risk of developing long-term sequelae. Thus, according to its ballistic advantage, an improvement of patient functional outcomes and a reduction of neurocognitive long-term toxicity are expected if tissue sparing proton-therapy is used .Randomized trial seems crucial to further assess proton-therapy indication for patients with cavernous sinus meningioma. METHODS: COG-PROTON-01 is the first worldwide randomized phase III prospective study evaluating long-term toxicity of these two irradiation modalities (PRT and XRT)for the treatment of cavernous sinus meningioma. Primary objective is to compare long-term cognitive and/or functional (visual, hearing, neurological and/or endocrinological) deterioration between patients treated by fractionated proton-therapy (PRT) or photon radiotherapy (XRT), 5 years after the end of irradiation. The primary endpoint is based on the individual neurocognitive test scores (grouped into five cognitive domains: attention, executive functioning, verbal memory, working memory, information processing speed) and on visual, hearing, endocrinological and neurological evaluations, five years after radiotherapy. Eligible patients with low-grade cavernous sinus meningioma will be 1:1 randomised, with stratification on age, sex, MoCA score. Overall, the inclusion of 160 patients is planned (80 in each arm). To be considered as positive, asumming that 47% of patients will not develop long-term cognitive disabilities deficits after XRT radiotherapy,, thus at least 70% of the patients treated with PRT should not develop functional impairment. First inclusions started on September 2023 (NCT05895344 ). TRIAL REGISTRATION: The study was registered on clinicaltrials.gov on June 8, 2023 with the following number: NCT05895344.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。